Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
Public ClinicalTrials.gov record NCT01667679. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted to determine if OPTINOSE SUMATRIPTAN delivered nasally (through the nose) using the OPTINOSE SUMATRIPTAN DEVICE can reduce the pain associated with migraine headaches in 30 minutes after use.
Study identification
- NCT ID
- NCT01667679
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 275 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2012 (Type not available)
- Primary completion
- Mar 2014 (Actual)
- Completion
- Jun 2014 (Actual)
- Last update posted
- Apr 12, 2017
2012 – 2014
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Clinical Research Center | San Francisco | California | 94109 | — |
| California Medical Clinic for Headache | Santa Monica | California | 90404 | — |
| Associated Neurologists of Southern CT, P.C. | Fairfied | Connecticut | 06824 | — |
| Premiere Research Institute | West Palm Beach | Florida | 33407 | — |
| MedVadis | Watertown | Massachusetts | 02472 | — |
| Michigan Head and Pain Institute | Ann Arbor | Michigan | 48104-5199 | — |
| ClinVest | Springfield | Missouri | 65807 | — |
| Mercy Health Research | St Louis | Missouri | 63141 | — |
| DENT Neurologic Institute | Amherst | New York | 14226 | — |
| Headache Welness Center | Greensboro | North Carolina | 27405 | — |
| PMG Research of Winston Salem, LLC | Winston-Salem | North Carolina | 27103 | — |
| Jefferson Headache Center | Philadelphia | Pennsylvania | 19107 | — |
| Coastal Carolina Research Center | Mt. Pleasant | South Carolina | 29464 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01667679, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2017 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01667679 live on ClinicalTrials.gov.